$14.000
+0.020 (+0.14%)Zum Schluss
VTYX-News
VTYX-Events
Significant Increases in Borrow Rates for Liquid Options
Latest data shows the largest indicative borrow rate increases among liquid option names include: PowerShares DB US Dollar Index Bullish Fund (UUP) 5.40% +1.09, VisionWave Holdings Inc (VWAV) 102.71% +1.00, T-REX 2X Long BMNR Daily Target ETF (BMNU) 30.17% +0.94, Star Bulk Carriers (SBLK) 2.23% +0.94, AXS TSLA Bear Daily ETF (TSLQ) 5.00% +0.60, GoPro (GPRO) 1.09% +0.56, Astex Pharmaceuticals Inc (ASTX) 13.96% +0.54, Gold Miners ETF (GDX) 1.16% +0.52, Tidal Trust II (IRE) 24.90% +0.48, and Ventyx Biosciences (VTYX) 0.80% +0.46.
Oppenheimer Downgrades Ventyx Biosciences to Perform After Eli Lilly's $14 Acquisition
Oppenheimer analyst Jeff Jones downgraded Ventyx Biosciences to Perform from Outperform without a price target after after Eli Lilly entered an agreement to acquire all outstanding shares of Ventyx for $14 in cash.
Canaccord Downgrades Ventyx Biosciences to Hold, Price Target Cut to $14
Canaccord analyst Edward Nash downgraded Ventyx Biosciences to Hold from Buy with a price target of $14, down from $16, after the company entered into an agreement for Eli Lilly to acquire it at a price of $14 per share in an all-cash transaction. The firm believes the acquisition will not encounter any antitrust issues.
Clear Street Downgrades Ventyx Biosciences to Hold, Price Target Raised to $14
Clear Street analyst Kaveri Pohlman downgraded Ventyx Biosciences (VTYX) to Hold from Buy with a price target of $14, up from $11, after Eli Lilly (LLY) agreed to acquire Ventyx for $1.2B. Eli Lilly is a "logical" buyer given its focus on cardiometabolic health, immunology, and neuroscience, which aligns with Ventyx's programs, the analyst tells investors in a research note. The firm added that Lilly currently lacks NLRP3 assets, suggesting Ventyx's portfolio would complement its cardiometabolic and neurodegenerative franchises and could pair with existing therapies.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.